Roche has announced plans to invest up to US $550 million in its diagnostics manufacturing site in Indianapolis by 2030.
Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group – the world's largest biotech company. This latest expansion underscores Roche's commitment to advancing science, driving innovation, and delivering cutting-edge solutions that improve patient outcomes. It follows the recent news that the company plans to invest US $50 billion into the United States of America over the next five years
The Indianapolis campus houses key operations, including US research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces approximately 5.2 billion Accu-Chek diabetes test strips annually and serves as one of two global distribution hubs focused on serving the US market and supporting distribution to 53 countries worldwide.
The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems. With more than 38 million Americans living with diabetes, access to effective disease management solutions is crucial. To address this growing need, Roche is investing in a new CGM manufacturing facility in Indianapolis. CGM technologies offer essential support for daily diabetes management, and this investment will help advance Roche's mission to improve patient care through innovation.
The expansion is expected to generate hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana's economy. It will also enhance domestic production capabilities and reduce dependency on imports – aligning with national efforts to strengthen local manufacturing.